Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique aims to cut heart failure risk

NCT ID NCT05015660

Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a newer pacing method called left bundle branch pacing (LBBP) with standard right ventricular pacing in 1,300 people who need a pacemaker for heart block. Standard pacing can sometimes weaken the heart over time, leading to heart failure. LBBP tries to mimic the heart's natural electrical system to avoid that. The trial will track heart failure events, heart function, and survival over several years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Left bundle branch pacing lead (device) vs right ventricular active fixation lead (device)
What this could lead to
If successful, this could show that left bundle pacing lowers the risk of heart failure and death compared to standard pacing, offering a better pacing option for patients with heart block.
What could go wrong
This is a large but still ongoing trial, and results may not show a clear benefit. The procedure is newer and may have unknown risks or be less effective in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Patients with an ejection fraction of \>35% 3. Patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated RV pacing is \>90% including: 1. Third degree AV block 2. Symptomatic or asymptomatic second-degree AV block 3. First degree AV block ≥ 280ms with a narrow QRS, or ≥ 240ms with an intraventricular delay (QRS duration ≥120ms) 4. Echocardiogram within the last 3 months, with ability to have DICOM images Exclusion Criteria: 1. Indication for an implantable cardioverter defibrillator 2. Presence of a mechanical tricuspid valve 3. Any prior attempt at implantation of an ICD, CRT, HBP, or LBBP 4. Lack of capacity to consent 5. Other serious medical condition with life expectancy of \<2 years 6. Pregnancy 7. Patients in whom the conduction system abnormality is expected to be transient or recover over time 8. Patients with permanent atrial fibrillation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart block are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrioventricular block atrioventricular dissociation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart block Pacemaker DDD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McGill University Health Centre-Research Institute

    RECRUITING

    Montreal, Quebec, H3Y2T6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.